This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This guide analyzes beta values across leading coins to identify those with the lowest market sensitivity. Explore interpretation and strategy tips.
26,582 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Projections show a potential drop to 78% of promised Social Security benefits by 2032 if rules stay the same. Retiree...
Florida’s housing boom faces a growing threat: AI-enabled deed and title fraud. This report outlines the risks and pr...
Analysts survey a pivot in AI monetization that could revive the Magnificent Seven's earnings trajectory in H2 2026, ...
A Brixton bank branch faced a bold scam when a man wore an old G4S uniform to obtain cash. This is how the asked cash...
Bitcoin has staged a rebound but faces a pivotal test near mid-$60,000s. This bitcoin price analysis: ready framework...
The ITA ETF just ripped higher again, underscoring a multi-year upcycle in America’s rearmament push. Here’s what inv...
Tech volatility hits highest levels this week as the Nasdaq 100 experiences bigger swings. The broader market psychol...
A new Gallup survey ties regular AI use to lower layoff risk in the U.S. job market. The findings challenge the idea...
As July unfolds, investors are eyeing three powerful nuclear energy stocks as policy momentum and grid demand bolster...
More than 30 confirmed screwworm cases have been reported in Texas and New Mexico, including two dogs. Vets issue urg...
Even with a seven-figure savings balance, retirees face higher living costs and market swings that can erode purchasi...